Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Efungumab, an antibody targeting Heat Shock Protein 90 Homolog.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Abagovomab, an antibody targeting MUC16.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Tanezumab, an antibody targeting NGFB.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Farletuzumab, an antibody targeting Folate receptor alpha.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Girentuximab, an antibody targeting CA9.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Clivatuzumab, an antibody targeting MUC1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Onartuzumab, an antibody targeting MET.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Ganitumab, an antibody targeting IGF-1R.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Fulranumab, an antibody targeting NGFB.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Tabalumab, an antibody targeting TNFSF13B.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Lampalizumab, an antibody targeting CFD.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Fasinumab, an antibody targeting NGFB.